Oncimmune, a De Soto bioscience company, has a test called EarlyCDT-Lung, an early cancer detection test, on the market.  Patient serum samples are tested for certain antibodies indicative of lung cancer.  Clinical lab scientist Matthew Kolarik taps and swirls the assay plates to mix the color indicator with the patient sample it is read Friday, July 8, 2011.  JILL TOYOSHIBA/The Kansas City Star 07082011
Oncimmune, a De Soto bioscience company, has a test called EarlyCDT-Lung, an early cancer detection test, on the market. Patient serum samples are tested for certain antibodies indicative of lung cancer. Clinical lab scientist Matthew Kolarik taps and swirls the assay plates to mix the color indicator with the patient sample it is read Friday, July 8, 2011. JILL TOYOSHIBA/The Kansas City Star 07082011
Oncimmune, a De Soto bioscience company, has a test called EarlyCDT-Lung, an early cancer detection test, on the market. Patient serum samples are tested for certain antibodies indicative of lung cancer. Clinical lab scientist Matthew Kolarik taps and swirls the assay plates to mix the color indicator with the patient sample it is read Friday, July 8, 2011. JILL TOYOSHIBA/The Kansas City Star 07082011